FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, I	D.C.	20549
---------------	------	-------

STATEMENT C	F CHANGES	IN BENEFICIAL	OWNERSHIP
	. 0.1,	III BEITEI IOIXE	O TTTLE TOTAL

ı	OMB APPRO	VAL						
	OMB Number:	3235-0287						
l	Estimated average burden							
	hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>TILTON GLENN F</u>				2. Issuer Name and Ticker or Trading Symbol AbbVie Inc. [ABBV]								heck all appl	icable) or	Person(s) to Is	wner	
(Last) (First) (Middle) 1 N. WAUKEGAN ROAD				3. Date of Earliest Transaction (Month/Day/Year) 06/30/2014							Office below	r (give title)	Other below)	(specify		
(Street) NORTH CHICAC			50064 Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)							ne) X Form	r Joint/Group Filing (Check Applicable n filed by One Reporting Person n filed by More than One Reporting on			
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				Date	Execution Date,			Code (I	Transaction Disposed Of (D) (Instr. 3, 4				Benefic	es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V Amount (A) or (D)			Price	Trancac	tion(s)		(IIISU. 4)					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date E. (Month/Day/Year) if	3A. Deemed Execution Da if any (Month/Day/Y	Co	ansactio de (Inst	n of E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Co	de V	(A)	(D)	Date Exercisable		opiration	Title	Amount or Number of Shares				
Stock Equivalent Units	\$0 ⁽¹⁾	06/30/2014		A	A	611		(1)		(1)	Common Stock	611	\$56.44	18,671 ⁽²⁾	D	

Explanation of Responses:

- 1. Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.
- 2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Steven L. Scrogham, attorney-07/02/2014 in-fact for Glenn F. Tilton

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.